PMID- 35870947
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220910
IS  - 1743-7075 (Print)
IS  - 1743-7075 (Electronic)
IS  - 1743-7075 (Linking)
VI  - 19
IP  - 1
DP  - 2022 Jul 23
TI  - Protective and therapeutic effectiveness of taurine supplementation plus low 
      calorie diet on metabolic parameters and endothelial markers in patients with 
      diabetes mellitus: a randomized, clinical trial.
PG  - 49
LID - 10.1186/s12986-022-00684-2 [doi]
LID - 49
AB  - BACKGROUND: Taurine supplementation as a sulfur-containing amino acid may 
      attenuate and/or alleviate diabetes-induced complications and endothelial 
      dysfunction via its anti-inflammatory and antioxidant activities. Our purpose was 
      to investigate the effect of Taurine supplementation on endothelial dysfunction 
      markers, oxidative stress, inflammation, and glycemic control in patients with 
      type 2 diabetes mellitus (T2DM). METHODS: In the current clinical trial, 120 
      patients with T2DM were randomly allocated to take either Taurine (containing 1 g 
      Taurine, n = 60) or placebo (n = 60) three times per day for an eight-week 
      period. Moreover, all patients were on a low-calorie diet. The primary outcome 
      was fasting blood glucose (FBG) and endothelial markers including sera 
      intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 
      (VCAM), and matrix metallopeptidase 9 (MMP-9). The secondary outcome was dietary 
      intake, anthropometric indices, serum insulin and Homeostatic Model Assessment of 
      Insulin Resistance (HOMA-IR), total antioxidant capacity (TAC), tumor necrosis 
      factor (TNF), high-sensitivity C-reactive protein (hs-CRP), malondialdehyde 
      (MDA), and lipid profile. RESULTS: After 8 weeks, Taurine-supplemented patients 
      had a considerable decrease in serum insulin and HOMA-IR compared to placebo 
      group. However, Taurine supplementation did not improve other metabolic 
      parameters including lipid profiles, glycated hemoglobin, and fasting blood 
      glucose (FBG). There was a significant decline in MDA, TNF, and hs-CRP levels 
      after these eight-week period of Taurine supplementation. In addition, the 
      Taurine group had fewer serum levels of endothelial dysfunction markers than the 
      placebo group. CONCLUSIONS: The evidence from our study revealed that Taurine 
      supplementation significantly reduced insulin and HOMA-IR, as well as oxidative 
      stress, inflammation, and endothelial markers in individuals with T2DM. Trial 
      registration The protocol of the study was recorded in the Iranian Registry of 
      Clinical Trials (IRCT20180712040438N3).
CI  - (c) 2022. The Author(s).
FAU - Moludi, Jalal
AU  - Moludi J
AUID- ORCID: 0000-0002-8333-414X
AD  - School of Nutritional Sciences and Food Technology, Kermanshah University of 
      Medical Sciences, Kermanshah, 5166614711, Iran. jmoludi@yahoo.com.
AD  - Behavioral Disease Research Center, Kermanshah University of Medical Sciences, 
      Kermanshah, Iran. jmoludi@yahoo.com.
FAU - Qaisar, Shaimaa A
AU  - Qaisar SA
AD  - Chemistry Department, College of Education, University of Garmian, Sulimmania, 
      Iraq.
FAU - Kadhim, Mustafa M
AU  - Kadhim MM
AD  - Department of Medical Laboratory Techniques, Dijlah University College, Baghdad, 
      10021, Iraq.
AD  - Medical Laboratory Techniques Department, Al-Farahidi University, Baghdad, Iraq.
FAU - Ahmadi, Yasin
AU  - Ahmadi Y
AD  - Behavioral Disease Research Center, Kermanshah University of Medical Sciences, 
      Kermanshah, Iran.
FAU - Davari, Mina
AU  - Davari M
AD  - Tabriz University of Medical Sciences, Tabriz, Iran.
LA  - eng
SI  - IRCT/IRCT20180712040438N3
PT  - Journal Article
DEP - 20220723
PL  - England
TA  - Nutr Metab (Lond)
JT  - Nutrition & metabolism
JID - 101231644
EIN - Nutr Metab (Lond). 2022 Sep 9;19(1):62. PMID: 36085214
PMC - PMC9308194
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Endothelial markers
OT  - Glycemic control
OT  - Inflammation
OT  - Taurine
COIS- The authors declare that there is no competing interests.
EDAT- 2022/07/24 06:00
MHDA- 2022/07/24 06:01
PMCR- 2022/07/23
CRDT- 2022/07/23 23:35
PHST- 2021/07/11 00:00 [received]
PHST- 2022/05/31 00:00 [accepted]
PHST- 2022/07/23 23:35 [entrez]
PHST- 2022/07/24 06:00 [pubmed]
PHST- 2022/07/24 06:01 [medline]
PHST- 2022/07/23 00:00 [pmc-release]
AID - 10.1186/s12986-022-00684-2 [pii]
AID - 684 [pii]
AID - 10.1186/s12986-022-00684-2 [doi]
PST - epublish
SO  - Nutr Metab (Lond). 2022 Jul 23;19(1):49. doi: 10.1186/s12986-022-00684-2.